Induction therapy: Why, when, and which agent?

Pediatric Transplantation

Volumn 14, Issue 3, 2010, Pages 298-313

  Krischock, Leah ^a   Marks, Stephen D ^b  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Adhesion molecules; Induction therapy; Monoclonal antibodies; Pediatrics; Polyclonal antibodies; Solid organ transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CD20 ANTIBODY; CD3 ANTIBODY; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ODULIMOMAB; OKT 3; PLACEBO; POLYCLONAL ANTIBODY; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; CD3 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ACUTE GRAFT REJECTION; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ASEPTIC MENINGITIS; ASPIRATION PNEUMONIA; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; BACTERIAL INFECTION; BRAIN DISEASE; BRAIN HEMORRHAGE; BRONCHOPNEUMONIA; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; GRAVES DISEASE; HEADACHE; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTESTINE INJURY; INTESTINE TRANSPLANTATION; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EDEMA; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PANCYTOPENIA; PEDIATRIC SURGERY; PROTEIN EXPRESSION; PRURITUS; REVIEW; RISK FACTOR; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CHILD; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION TOLERANCE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTILYMPHOCYTE SERUM; CELL ADHESION MOLECULES; CHILD; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; TRANSPLANTATION TOLERANCE;

EID: 77950675702     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2009.01290.x     Document Type: Review

References (85)

1. Tan HP, Smaldone MC, Shapiro R. Immunosuppressive preconditioning or induction regimens: Evidence to date. Drugs 2006 : 66 : 1535 1545.
2. North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2008 Annual Report. 2009.
3. Technology Appraisal 99. Immunosuppressive therapy for renal transplantation in children and adolescents. April 2006. National Institute for Health and Clinical Excellence
4. Kirk AD. Induction immunosuppression. Transplantation 2006 : 82 : 593 602.
5. Ashley C, Currie A (eds) The Renal Drug Handbook, 3rd edn.
6. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004 : 351 : 2715 2729.
7. Hale DA. Biological effects of induction immunosuppression. Curr Opin Immunol 2004 : 16 : 565 570.
8. Monaco AP. Immunosuppression and tolerance for clinical organ allografts. Curr Opin Immunol 1989 : 1 : 1174 1177.
9. Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, Cerilli GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 1967 : 124 : 301 308.
10. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991 : 51 : 669 673.
11. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997 : 100 : 1199 1203. (Pubitemid 27386305)
12. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994 : 57 : 685 694. (Pubitemid 24106766)
13. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995 : 59 : 1194 1200.
14. Colovai AI, Vasilescu ER, Foca-Rodi A, et al. Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies. Hum Immunol 2005 : 66 : 501 512. (Pubitemid 40797548)
15. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998 : 128 : 817 826.
16. Hastings MC, Wyatt RJ, Lau KK, et al. Five years' experience with thymoglobulin induction in a pediatric renal transplant population. Pediatr Transplant 2006 : 10 : 805 810.
17. Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003 : 75 : 844 851. (Pubitemid 36373458)
18. Boucek RJ Jr., Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: A multicenter study. J Heart Lung Transplant 1999 : 18 : 460 469. (Pubitemid 29256357)
19. Pollock-Barziv SM, Allain-Rooney T, Manlhiot C, et al. Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant recipients; experience and outcomes with a novel strategy for administration. Pediatr Transplant 2009 : 13 : 585 589.
20. Bonaros N, Dunkler D, Kocher A, et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. J Heart Lung Transplant 2006 : 25 : 1154 1163. (Pubitemid 44311527)
21. Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004 : 78 : 779 781. (Pubitemid 39244749)
22. Jimenez J, Kapadia SR, Yamani MH, et al. Cellular rejection and rate of progression of transplant vasculopathy: A 3-year serial intravascular ultrasound study. J Heart Lung Transplant 2001 : 20 : 393 398. (Pubitemid 32303143)
23. Zhang R, Haverich A, Struber M, Simon A, Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant 2008 : 27 : 603 609. (Pubitemid 351711706)
24. Vianna RM, Mangus RS, Fridell JA, Weigman S, Kazimi M, Tector J. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 2008 : 85 : 1290 1293. (Pubitemid 351670479)
25. McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: Disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol 2002 : 169 : 2736 2746.
26. Baan CC, van Riemsdijk-Overbeeke IC, Boelaars-van Haperen MJ, Ijzermans JM, Weimar W. Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients. Transpl Immunol 2002 : 10 : 81 87.
27. Kircher B, Latzer K, Gastl G, Nachbaur D. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 2003 : 134 : 426 430.
28. Vincenti F. Current use and future trends in induction therapy. Saudi J Kidney Dis Transpl 2005 : 16 : 506 513.
29. Grego K, Arnol M, Bren AF, Kmetec A, Tomazic J, Kandus A. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. Transplant Proc 2007 : 39 : 3093 3097.
30. Nair MP, Nampoory MR, Johny KV, et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 2001 : 33 : 2767 2769.
31. Lin M, Ming A, Zhao M. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: A clinical study. Clin Transplant 2006 : 20 : 325 329.
32. Bunnapradist S, Hong A, Lee B, Takemoto SK. Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches. Transplant Proc 2005 : 37 : 886 888.
33. Brennan DC, Daller JA, Lake KD, Cibrik D, Del CD. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006 : 355 : 1967 1977.
34. Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008 : 359 : 1736 1738.
35. Webb NJ, Prokurat S, Vondrak K, et al. Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: Two-year follow-up data. Pediatr Nephrol 2009 : 24 : 177 182.
36. Grenda R, Watson A, Vondrak K, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant 2006 : 6 : 1666 1672.
37. Offner G, Toenshoff B, Hocker B, et al. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 2008 : 86 : 1241 1248.
38. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 2004 : 77 : 166 176.
39. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 2006 : 81 : 1542 1548. (Pubitemid 43890891)
40. Carrier M, Leblanc MH, Perrault LP, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: A non-inferiority trial. J Heart Lung Transplant 2007 : 26 : 258 263. (Pubitemid 46341886)
41. Mattei MF, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007 : 26 : 693 699. (Pubitemid 47001715)
42. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005 : 24 : 1297 1304. (Pubitemid 41247813)
43. Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005 : 24 : 1327 1331.
44. Ford KA, Cale CM, Rees PG, Elliott MJ, Burch M. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant 2005 : 24 : 1284 1288. (Pubitemid 41247811)
45. Asensio M, Margarit C, Chavez R, Ortega J, Charco R, Iglesias J. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. Transplant Proc 2002 : 34 : 1970 1971.
46. Spada M, Petz W, Bertani A, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant 2006 : 6 : 1913 1921. (Pubitemid 44024964)
47. Lupo L, Panzera P, Tandoi F, et al. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: A prospective randomized clinical trial. Transplantation 2008 : 86 : 925 931.
48. Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999 : 159 : 829 833.
49. Hachem RR, Chakinala MM, Yusen RD, et al. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant 2005 : 24 : 1320 1326.
50. Borro JM, De la TM, Miguelez C, Fernandez R, Gonzalez D, Lemos C. Comparative study of basiliximab treatment in lung transplantation. Transplant Proc 2005 : 37 : 3996 3998. (Pubitemid 43015235)
51. Burton CM, Andersen CB, Jensen AS, et al. The incidence of acute cellular rejection after lung transplantation: A comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 2006 : 25 : 638 647.
52. Mullen JC, Oreopoulos A, Lien DC, et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007 : 26 : 504 510. (Pubitemid 46602005)
53. Van Wauwe JP, De M Jr., Goossens JG. OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980 : 124 : 2708 2713.
54. Norman DJ, Vincenti F, de Mattos AM, et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000 : 70 : 1707 1712. (Pubitemid 32064824)
55. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999 : 68 : 1632 1637. (Pubitemid 30004793)
56. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999 : 68 : 608 616.
57. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988 : 2 : 1394 1399.
58. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003 : 76 : 120 129.
59. Knechtle SJ, Pirsch JD, Fechner H, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003 : 3 : 722 730.
60. Bloom DD, Hu H, Fechner JH, Knechtle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006 : 81 : 81 87.
61. Hale G, Bright S, Chumbley G, et al. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement. Blood 1983 : 62 : 873 882.
62. Hale G, Hoang T, Prospero T, Watt SM, Waldmann H. Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1983 : 1 : 305 319.
63. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989 : 73 : 1431 1439.
64. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004 : 78 : 426 433.
65. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002 : 99 : 2586 2591.
66. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003 : 101 : 1422 1429.
67. Hale G, Waldmann H, Dyer M. Specificity of monoclonal antibody Campath-1. Bone Marrow Transplant 1988 : 3 : 237 239.
68. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006 : 19 : 705 714.
69. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998 : 351 : 1701 1702.
70. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999 : 68 : 1613 1616.
71. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005 : 5 : 1347 1353.
72. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004 : 136 : 754 760.
73. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006 : 148 : 813 818.
74. Schadde E, D'Alessandro AM, Knechtle SJ, et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl Int 2008 : 21 : 625 636.
75. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007 : 7 : 2619 2625.
76. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997 : 25 : 705 708.
77. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004 : 4 : 996 1001.
78. Muorah MR, Brogan PA, Sebire NJ, Trompeter RS, Marks SD. Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss. Pediatr Transplant 2009 : 13 : 217 222.
79. O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol 2005 : 174 : 3781 3788.
80. von WE, Lautenschlager I, Krogerus L, Hayry P, Isoniemi H, Salmela K. Adhesion molecules and activation markers in acute rejection of human renal allografts. Transpl Immunol 1996 : 4 : 57 58. (Pubitemid 26167062)
81. Cosimi AB, Conti D, Delmonico FL, et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990 : 144 : 4604 4612.
82. Salmela K, Wramner L, Ekberg H, et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 1999 : 67 : 729 736.
83. Kuypers DR, Vanrenterghem YF. Monoclonal antibodies in renal transplantation: Old and new. Nephrol Dial Transplant 2004 : 19 : 297 300.
84. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as an induction treatment in first kidney transplantations. Transplantation 1996 : 62 : 1565 1570.
85. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter-trial of efalizumab, a humanized andti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007 : 7 : 1770 1777.